• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

群体药代动力学分析在日本儿科患者的非索非那定。

Population pharmacokinetic analysis of fexofenadine in Japanese pediatric patients.

机构信息

Disposition, Safety and Animal Research, Drug Disposition, Modeling and Simulations Entity, Sanofi-aventis Recherche & Développement, 371, rue du Professeur Joseph Blayac, 34184, Montpellier Cedex 04, France,

出版信息

J Pharmacokinet Pharmacodyn. 2014 Apr;41(2):187-95. doi: 10.1007/s10928-014-9356-2. Epub 2014 Mar 16.

DOI:10.1007/s10928-014-9356-2
PMID:24633780
Abstract

A population pharmacokinetic analysis was conducted to characterize the pharmacokinetics of fexofenadine in Japanese pediatric patients (6 months through 16 years) with perennial allergic rhinitis or atopic dermatitis. The dataset was composed of 515 patients (including 109 adults), for a total of 1,080 concentration-time points. The analysis was performed with NONMEM using the SAEM method. Several structural models and residual error models were evaluated. The relationship between the individual estimates and the potential covariates was then investigated: demographic and pathophysiologic characteristics were tested as potential model covariates (forward selection method). The qualification of the model was performed using visual predictive check and bootstrap. A two-compartment disposition model with first-order absorption best fitted the data. The inter-individual variability was modeled through an exponential error model for all parameters (except for ka for which no inter-individual term could be estimated), while a proportional error model was used to model the residual variability. The final model included two covariates on elimination clearance and one on the intercompartmental clearance. CL/F was related to BSA and patient's age (expressed in months) Q/F was also related to BSA. Once the model was correctly qualified, exposure parameters such as Cmax and AUCτ were computed and compared between each age sub-group and between Japanese and Caucasians patients. These comparisons did not reveal any major difference (less than 50 %) between subgroups.

摘要

进行了群体药代动力学分析,以描述患有常年性变应性鼻炎或特应性皮炎的日本儿科患者(6 个月至 16 岁)中非索非那定的药代动力学特征。该数据集由 515 名患者(包括 109 名成年人)组成,共 1080 个浓度-时间点。使用 NONMEM 通过 SAEM 方法进行分析。评估了几种结构模型和残留误差模型。然后研究了个体估计值与潜在协变量之间的关系:测试了人口统计学和病理生理学特征作为潜在的模型协变量(前向选择方法)。使用可视化预测检查和自举法对模型进行了资格验证。具有一级吸收的两室处置模型最适合数据。通过指数误差模型对所有参数(ka 除外,因为无法估计个体间项)进行个体间变异性建模,而使用比例误差模型对残留变异性进行建模。最终模型包括两个消除清除率的协变量和一个隔室间清除率的协变量。CL/F 与 BSA 和患者年龄(以月表示)相关,Q/F 也与 BSA 相关。一旦模型得到正确验证,就计算了 Cmax 和 AUCτ 等暴露参数,并在每个年龄亚组之间以及日本和白种人患者之间进行了比较。这些比较并未显示亚组之间存在任何重大差异(小于 50%)。

相似文献

1
Population pharmacokinetic analysis of fexofenadine in Japanese pediatric patients.群体药代动力学分析在日本儿科患者的非索非那定。
J Pharmacokinet Pharmacodyn. 2014 Apr;41(2):187-95. doi: 10.1007/s10928-014-9356-2. Epub 2014 Mar 16.
2
The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride.混合效应协变量分析在儿科受试者快速剂量选择中的应用:以盐酸非索非那定为例的案例研究
Biopharm Drug Dispos. 2004 Dec;25(9):373-87. doi: 10.1002/bdd.425.
3
Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children.组胺H1受体拮抗剂依巴斯汀在成人和儿童中的群体药代动力学。
Br J Clin Pharmacol. 2005 Jan;59(1):43-53. doi: 10.1111/j.1365-2125.2005.2250.
4
Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.多柔比星的群体药代动力学:成人和 3 岁以上儿童 NONMEM 模型的建立。
Cancer Chemother Pharmacol. 2013 Mar;71(3):749-63. doi: 10.1007/s00280-013-2069-1. Epub 2013 Jan 13.
5
Population pharmacokinetics of terfenadine.特非那定的群体药代动力学。
Pharm Res. 1996 Jun;13(6):832-8. doi: 10.1023/a:1016036624935.
6
Suppression of the histamine-induced wheal and flare response by fexofenadine HCl 60 mg twice daily, loratadine 10 mg once daily and placebo in healthy Japanese volunteers.健康日本志愿者每日两次服用60毫克盐酸非索非那定、每日一次服用10毫克氯雷他定及安慰剂对组胺诱导的风团和潮红反应的抑制作用。
Curr Med Res Opin. 2005 Sep;21(9):1495-503. doi: 10.1185/030079905X59175.
7
The effects of acute doses of fexofenadine, promethazine, and placebo on cognitive and psychomotor function in healthy Japanese volunteers.急性剂量的非索非那定、异丙嗪和安慰剂对健康日本志愿者认知及精神运动功能的影响。
Ann Allergy Asthma Immunol. 2003 Apr;90(4):404-10. doi: 10.1016/S1081-1206(10)61824-8.
8
Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.伊曲康唑对非索非那定药代动力学和药效学的影响与多药耐药基因1(MDR1)基因多态性的关系
Clin Pharmacol Ther. 2005 Aug;78(2):191-201. doi: 10.1016/j.clpt.2005.04.012.
9
The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis.盐酸非索非那定与伪麻黄碱单独及联合使用治疗季节性变应性鼻炎的疗效与安全性。
J Allergy Clin Immunol. 1999 Jul;104(1):100-6. doi: 10.1016/s0091-6749(99)70120-x.
10
Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.伊曲康唑和地尔硫䓬对P-糖蛋白底物非索非那定药代动力学的影响。
Br J Clin Pharmacol. 2006 May;61(5):538-44. doi: 10.1111/j.1365-2125.2006.02613.x.

引用本文的文献

1
Improving Understanding of Fexofenadine Pharmacokinetics to Assess Pgp Phenotypic Activity in Older Adult Patients Using Population Pharmacokinetic Modeling.运用群体药代动力学模型增进对非索非那定药代动力学的理解,以评估老年患者中P-糖蛋白的表型活性。
Clin Pharmacokinet. 2025 Feb;64(2):275-283. doi: 10.1007/s40262-024-01470-4. Epub 2025 Jan 11.
2
Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics.人类膜转运蛋白的发展:药物处置与药物遗传学
Clin Pharmacokinet. 2016 May;55(5):507-24. doi: 10.1007/s40262-015-0328-5.

本文引用的文献

1
Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.用于诊断非线性混合效应模型的预测校正可视化预测检验。
AAPS J. 2011 Jun;13(2):143-51. doi: 10.1208/s12248-011-9255-z. Epub 2011 Feb 8.
2
Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.非索非那定的药代动力学:微剂量评估和绝对口服生物利用度评估。
Eur J Pharm Sci. 2010 May 12;40(2):125-31. doi: 10.1016/j.ejps.2010.03.009. Epub 2010 Mar 20.
3
Dosing in children.儿童用药剂量。
Clin Pharmacol Ther. 2010 Mar;87(3):367-70. doi: 10.1038/clpt.2009.262. Epub 2010 Jan 20.
4
Facilitation of drug evaluation in children by population methods and modelling.运用群体方法和模型促进儿童药物评估。
Clin Pharmacokinet. 2008;47(4):231-43. doi: 10.2165/00003088-200847040-00002.
5
Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.地氯雷他定、非索非那定和左西替利嗪的临床药代动力学与药效学:一项比较性综述
Clin Pharmacokinet. 2008;47(4):217-30. doi: 10.2165/00003088-200847040-00001.
6
The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride.混合效应协变量分析在儿科受试者快速剂量选择中的应用:以盐酸非索非那定为例的案例研究
Biopharm Drug Dispos. 2004 Dec;25(9):373-87. doi: 10.1002/bdd.425.
7
A Linux cluster for population pharmacokinetic analyses.用于群体药代动力学分析的Linux集群。
Int J Clin Pharmacol Ther. 2004 Mar;42(3):189-90.
8
Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.使用后验预测检验评估药代动力学/药效学模型。
J Pharmacokinet Pharmacodyn. 2001 Apr;28(2):171-92. doi: 10.1023/a:1011555016423.
9
A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models.一种用于生成自抽样样本以验证非线性混合效应群体模型的方法。
Comput Methods Programs Biomed. 1999 Apr;59(1):19-29. doi: 10.1016/s0169-2607(98)00098-4.
10
A size standard for pharmacokinetics.药代动力学的尺寸标准。
Clin Pharmacokinet. 1996 May;30(5):329-32. doi: 10.2165/00003088-199630050-00001.